cyrilzakka/clinical-trials huggingface dataset:
Personalised Cognitive Remediation Therapy (pCRT)

Cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia. There is evidence that Cognitive Remediation Therapy, a form of psychological therapy, is effective in improving cognition and functioning but there is still a limited understanding of what influence people's different response to this therapy. A tailored treatment is likely to be more effective because it will adapt to service users' unique characteristics.

The investigators are planning a study exploring at the feasibility and acceptability of novel form of Cognitive Remediation Therapy which is personalised (pCRT) to the person individual characteristics. The personalised therapy will consist of task practice using computerized Cognitive Remediation software (i.e. called CIRCuiTS). The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.

Cognitive deficits in people with psychosis have been shown to have negative impact on functional goals including the ability to work and perform daily tasks. Cognitive Remediation Therapy (CRT) is a psychological therapy developed to improve cognitive functions in people with schizophrenia but ultimately with a focus on improving social and functional outcomes. There is evidence that CRT is effective in improving cognition and functioning but there is still a limited understanding of the mechanisms responsible for different treatment responses. This study attempts to fill this gap by developing and testing a new form of CRT, which will personalise therapy elements according to participants' characteristics. The therapy will consist of task practice using a computerised Cognitive Remediation software and supervised activities supported by a therapist to boost functioning. The knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.

Eligibility Criteria:
Inclusion Criteria:

* a range of 18-65 years
* English speaking or with a good knowledge of the language
* a diagnosis of schizophrenia or schizoaffective disorder according to the DSM- V
* at least one year contact with mental health services,
* a deficit (of at least one standard deviation below the mean) in at least one cognitive domain out of these three cognitive domains: memory, executive function and information processing.

Exclusion Criteria:

* Planned medication change
* Diagnosis of learning disability
* Presence of cognitive deficits related to organic causes or head injury
* Primary diagnosis of substance dependence
Is There a Comorbidity Between Migraine and Allergic Rhinitis?

The researchers investigated the relationship between migraine and allergy. For this purpose, the researchers designed a controlled study to evaluate nasal symptoms and signs; and to perform Specific Immunoglobulin E (IgE) measurements in migraine patients and healthy subjects. According to these results the prevalence of allergic rhinitis in migraine group was planned to be compared to that of the healthy controls, statistically.


Eligibility Criteria:
Inclusion Criteria:

* patients with migraine

Exclusion Criteria:

* other neurologic disorders that may contribute to headaches, such as stroke, cerebral palsy, trigeminal neuralgia, and seizure disorder
* also acute and chronic sinusitis.
European Bifurcation Club Trial - Two-stent Versus One-stent Technique for Large Bifurcation Lesions

This study will examine use of two-stent versus one-stent techniques for patients with large calibre bifurcation lesions including significant side branch disease.

Treatment of bifurcation coronary lesions remains a difficult area, in which best practice is yet to be established. Prior to the era of drug-eluting stents, the limited data which existed suggested that a strategy of stenting the main vessel, with balloon angioplasty alone of the side-branch if required was superior to stenting both vessels.

Randomised trials of "all-comer" bifurcation lesions have now established that there is no advantage to systematic dual drug-eluting stent strategies. However, these trials included patients with no disease in the side branch, and small side branch vessels.

Expert consensus suggests that "large" bifurcations with significant ostial side branch disease still merit a systematic total lesion coverage stent technique. This trial therefore is designed to assess the hypothesis that large true bifurcations with significant side branch ostial disease are more successfully treated with a systematic culotte technique than with the provisional T approach.

Eligibility Criteria:
Inclusion Criteria:

* "True" coronary bifurcation lesion (i.e. \>50% lesion in both main vessel and side branch) requiring revascularisation
* Main vessel ≥ 2.5mm diameter (visual inspection)
* Side branch ≥ 2.5mm diameter (visual inspection)
* Side branch ostial lesion ≥5mm length
* Patient ≥18 years old
* Females of childbearing potential: -ve pregnancy test

Exclusion Criteria:

* Acute ST elevation myocardial infarction
* Cardiogenic shock
* Left main stem lesion of haemodynamic significance
* Chronic total occlusion of either vessel
* Additional Type C lesions requiring PCI
* Either bifurcation vessel not suitable for stenting
* Platelet count ≤50 x 109/mm3
* Left ventricular ejection fraction ≤20%
* Patient life expectancy less than 12 months
* Known allergies to aspirin, clopidogrel, heparin, stainless steel, intravenous contrast (severe), or stent drug elutant
* Participation in another investigational drug or device study
* Patient unable to give informed consent
Different Sessions of Perineural Injection With Dextrose for Carpal Tunnel Syndrome

Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. The technique of perineural injection therapy (PIT) by using 5% dextrose (D5W) is now commonly used for peeling the nerve from surrounding soft tissue (called nerve hydrodissection), which may help antineurogenic inflammation, allow the impulse to pass, and rescue the nerve with ischemic damage. However, the evidence and reference of PIT and nerve hydrodissection are very seldom until our series researches since 2017. Moreover, our research revealed PIT with D5W is more beneficial than that of corticosteroid in patients with mild-to-moderate CTS at 4 to 6 months postinjection. However, the accumulative effect and long-term effect (more than 6 months) of PIT is still unknown. Hence, we design a randomized, double- blind, controlled trail to assess the long-term effect of ultrasound-guided PIT in patients with CTS. The aim one is to survey the possible accumulative effect of different sessions of PIT (6 months follow-up) and aim two is to evaluate the long-term effect and safety of PIT (one year follow-up).

After obtaining written informed consent, patients clinically diagnosed with mild-to-moderate CTS were includes and randomized into three groups. Group A, patients received two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval); Group B, patients received one-session of ultrasound-guided PIT with 10cc D5W and 5cc normal saline separately (3 months interval); Group C (control group), patients received two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline. The primary outcome is Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and secondary outcomes include visual analog scale (VAS), cross-sectional area (CSA) of the median nerve, nerve conduction velocity of the median nerve, and Global assessment of treatment. The evaluations were performed pretreatment as well as on the 1st, 3rd, 6th, 9th month and one year after first injection.

Eligibility Criteria:
Inclusion Criteria:

* Age between 20-80 year-old.
* Diagnosis was confirmed using an electrophysiological study

Exclusion Criteria:

* Cancer
* Coagulopathy
* Pregnancy
* Inflammation status
* Cervical radiculopathy
* Polyneuropathy, brachial plexopathy
* Thoracic outlet syndrome
* Previously undergone wrist surgery or steroid injection for CTS
Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes

A randomized, controlled, parallel group design will be used to test whether a Secondhand Smoke Exposure program initiated in the hospital and completed in the home using motivational interviewing plus motivational incentives (MI+) is more effective than Conventional Care (CC) with Neonatal Incentives Care Unit Infants' parents.


Eligibility Criteria:
Inclusion Criteria:

* Have an infant that is at least 1 week prior to the estimated date of hospital discharge in the NICU at Children's Memorial Hermann Hospital (CMHH)
* Report at least one person living in the home who smokes
* Agree to attend intervention sessions and to invite other household members
* Live within 50 miles of our center
* Have access to a telephone.

Exclusion Criteria:

* Severe cognitive, and/or psychiatric impairment, per judgment of NICU and research staff, that precludes cooperation with study protocol
* Inability to read, write, and speak English or Spanish
* Inability or unwillingness to provide signed consent for participation
* Inability or unwillingness to meet study requirements, including home visits for data collection and intervention purposes.
Drug-screening in AML at Relapse for Targeted Treatment

This is a non-randomised clinical study investigating subsequent patients with specific AML treatment started between January 1, 2022 until December 31, 2022.

Patients with relapsing disease are planned to be analyzed in this study

The standard treatment for young fit patients with acute myeloid leukemia (AML) is intensive chemotherapy followed by consolidation treatment with curative intent. Usually, two cycles of intensive chemotherapy are given, with subsequent consolidation treatment depending on the genetic risk-assessment of the patients as well as on the response to the induction treatment.

For elderly or unfit patients, such an intensive approach is not feasible, and palliative treatment must be considered. The standard first-line-treatment for such patients since more than a decade comprises repetitive cycles of a hypomethylating agent (either Azacitidine or Decitabine). The median progression free survival following these approaches in this population is between 4 and 8 months, with an overall-survival of up to 12 months. More recently, the addition of the Bcl-2 inhibitor Venetoclax to hypomethylating agents has led to a modest improvement both of progression-free and overall survival. However, overall survival in such patients usually does not exceed 14-16 months.

The laboratory of Prof. Berend Snijder, Institute of Molecular Systems Biology, at the ETH (Eidgenössische Technische Hochschule) Zurich has developed an image-based ex-vivo drug screening platform for patients with aggressive haematological malignancies, also called pharmacoscopy. Using such a technique, leukemic cells from a patient at relapse can be rapidly screened for sensitivity to single compounds. A drug score is calculated for each compound.

Starting in Q2/2021, the investigator at the Department of Medical Oncology, University Hospital Inselspital in Bern, collected experiences using such an approach. Having received information from the laboratory on top sensitivity of leukemic cells of a given patient to a specific drug, a process is initiated to try to obtain access to such off-label drugs.

Eligibility Criteria:
Inclusion Criteria:

* Included are patients with AML at relapse treated at the Department of Medical Oncology at the University Hospital Inselspital in Bern.
* Patients are not planned to undergo intensive reinduction treatment with subsequent allogeneic hematopoietic transplantation in a curative intent.
* Patients have exhausted all standard therapeutic options and they must have no available licensed standard treatment for relapsed AML.
* Written informed consent

Exclusion Criteria:

* Patients able to undergo intensive reinduction treatment with subsequent allogeneic hematopoietic transplantation in a curative intent
* Patients have available standard therapeutic options
Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.

Cardiac imaging using standard-of-care Nuclear Medicine techniques assess the relative radiopharmaceutical distribution from coronary arteries to cardiac tissue. This standard interpretation however, lacks the clinical utility of modern quantitative techniques that are now routinely obtained during cardiac catheterization, such as fractional flow reserve (FFR). Cardiologists routinely base critical management decisions, including the choice for revascularization, stenting, or angioplasty, on these measurements.

Non-invasive measurements of MBF (Myocardial Blood Flow), CFR (Coronary Flow Reserve) and RFR (Relative Flow Reserve) using PET/CT have been investigated, but have yet to reach clinicl use. Given the inherent gains in sensitivity and resolution, digital PET/CT, may allow for a more robust and accurate platform to obtain quantitative measurements of MBF, CFR and RFR which may greatly enhance the clinical utility of cardiac PET/CT for management of coronary artery disease.

Eligibility Criteria:
Inclusion Criteria:

* Patient is ≥ 18 years old at the time of the scan
* Patient has known or suspected coronary artery disease
* Patient has had a recent or will be scheduled for a diagnostic coronary angiogram
* Patient provides written informed consent
* Patient is referred for myocardial perfusion scan
* Patient is capable of complying with study procedures
* Patient is able to remain still for duration of imaging procedure (approximately 60 minutes total for both PET/CT)

Exclusion Criteria:

* Patients who are pregnant or breast feeding
* Patients with contraindications to regadenoson
Impact of Environmental Exposures on Tumor Risk in Subjects at Risk of Hereditary SDHx Paraganglioma

The main objective of the pilot phase of PGLEXPO will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in SDHx-mutation carriers

The main objective of the pilot phase of PGLEXPO will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in SDHx-mutation carriers.

Patients will be selected from subjects with a mutation in one of the SDHx genes. The cases will have developed a tumor, while the controls will be tumor-free. Controls will be matched to the cases according to sex, age and type of gene affected. Past exposures will be sought through a telephone questionnaire.

Eligibility Criteria:
Inclusion Criteria:

1. Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor
2. Controls: SDHx mutation carriers with no SDHx-related tumor

Exclusion Criteria:

Incapacity to exercise free and informed consent for the study
Structured Trauma Quality Improvement Meetings at Four Trauma Centres in India

A prospective before-and-after study to evaluate the effect of implementing a Trauma Quality Improvement protocol on the process of Trauma Quality Improvement meetings and major trauma patient outcomes at four trauma centres in India.

This project will be conducted as a prospective before-and-after study at four major trauma centres in India, with the intervention occurring between pre- and post-intervention phases. Included in the study will be all patients presenting to any of the four trauma hospitals with a potentially life-threatening or limb-threatening injury. The intervention will be the introduction of a structured Trauma Quality Improvement Meeting (TQIM), using a checklist and training program. The primary outcome will be compliance with the TQIM checklist, measured as the proportion of discussed cases (trauma deaths) for which problems with care, preventability and corrective actions were discussed and / or agreed. The secondary outcomes will include in-hospital risk-adjusted mortality, hospital length of stay and time to emergency surgery. Data collection will occur at all meetings at the four trauma hospitals at which trauma deaths are discussed. Data will also be collected in a dedicated trauma registry.

Eligibility Criteria:
Inclusion Criteria:

* All patients presenting to any of the four study sites with a potentially life-threatening or limb-threatening injury. Specifically, all presenting injured patients triaged as "Red" or "Yellow" according to the Australia-India Trauma Systems Collaboration (AITSC) Trauma Triage Protocol, will meet the screening criteria for data collection. Retrospective inclusion in the registry will be continued for all screened patients presenting to any of the included hospitals with injury (including near-drowning) as the primary diagnosis and with at least one of the following criteria:

  * Admission to hospital
  * Death after triage but before admission

Exclusion Criteria:

* The exclusion criteria for the AITSC Trauma Registry are:

  * Death at scene
  * Alive at triage but not admitted to hospital
  * Isolated poisoning
  * Isolated burns
  * Single digit finger or toe amputations
Body Posture, Joint Mobility, and Trunk Muscle Endurance Related to Lower Back Pain in Tennis Players

The aim of this study was to determine the significance of the impact of external factors (self-evaluation of the subjects) and internal factors, including the range of motion in the spine and hip joints, trunk muscle endurance and body posture of tennis players, on the occurrence and severity of low back pain.

The aim of the study was to compare tennis players with and without lower back pain (LBP) and individuals not engaged in asymmetric sports without LBP in terms of spinal flexion, extension, lateral bending range of motion, hip joint flexion, extension, internal and external rotation, modified seat and reach test results, trunk muscle endurance, body posture parameters, and survey information regarding training volume and stretching exercises. Identifying significant differences between participants with and without LBP could provide indications for modifying rehabilitation programs for amateur tennis players with LBP or for introducing preventive exercises targeting factors significantly influencing the occurrence of LBP in this population. Prior to the study, participants provided written consent and were informed of their right to withdraw from the study at any time.

Eligibility Criteria:
Inclusion Criteria:

* provided written consent to participate in the study

For Study Group:

* playing tennis at least 3 times per week for the past 2 years
* experiencing back pain in the last 6 months that prevented playing tennis

For Comprarison Group I:

* playing tennis at least 3 times per week for the past 2 years
* no lower back pain (confirmed via survey) in the last 6 months that would have prevented playing tennis

For Comparison Group II:

* no lower back pain (confirmed via survey)
* regular physical activity at least 3 times a week
* no participation in asymmetrical sports

Exclusion Criteria:

* lack of written consent to participate in the study,
* history of surgical procedures involving the spine or torso,
* severe musculoskeletal pathologies in the medical history, such as previous cancers in the torso area, vertebral fractures, structural scoliosis,
* inability to assume the required test positions.
Uterine Artery Doppler and Menstrual Changes After Insertion Intrauterine Contraceptive Device

To evaluate the correlation between uterine artery Doppler indices and subsequent menstrual changes after 3 months of insertion of copper T-380 IUD and LNG-IUS

A randomized prospective clinical trial

Study Population:

The study population includes multiparous women, having normal menstrual cycles, who are eligible for insertion of IUCD. Women will be recruited for enrollment when they come to the family planning clinic. They will be counseled about different contraceptive options. If they want to have the IUCD, they will be asked to participate in the study after been evaluated to ensure fulfilling inclusion and exclusion criteria Women will be enrolled in the study after giving written informed consent Group (A): ....Women will have the copper T-380 IUD (PREGNA, India, imported by DKT Egypt LLC-Egypt) ® IUD.

Group (B): .... Women will recieve the LNG-IUS (Mirena, Bayer HealthCare, Berlin, Germany)® IUD .

Eligibility Criteria:
Inclusion Criteria:

* Desire to have intrauterine contraceptive device after counseling about different contraceptive options and consented to the study.
* Normal menstrual bleeding cycles (24-35 days).

Exclusion Criteria:

1. Nulliparity.
2. Undiagnosed uterine bleeding.
3. Any proven ovarian, uterine or endometrial pathology such as; uterine myoma, adenomyosis, endometrial polyps, ovarian cysts
4. Contraceptive pills had not been taken during the previous 3 months and any previous IUD had been removed at least 1 month earlier
5. Hemorrhagic disorders.
6. Acute or chronic pelvic inflammatory disease
7. Known uterine anomalies e.g., Bicornuate/septate Uterus.
8. Anemia (hemoglobin \<10 g/dl).
9. Diagnosis of active cervical infection
10. Dysplasia in the cervix.
11. Patients wishing post-partum or post-abortum IUD insertion